# Effect of the CFTR-modulating Triple Therapy Elexacaftor - Tezacaftor - Ivacaftor

> **NCT05576324** · — · UNKNOWN · sponsor: **University of Erlangen-Nürnberg Medical School** · enrollment: 130 (estimated)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** Elexacaftor / Ivacaftor / Tezacaftor

## Key facts

- **NCT ID:** NCT05576324
- **Lead sponsor:** University of Erlangen-Nürnberg Medical School
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-12-30
- **Primary completion:** 2023-10-18
- **Final completion:** 2023-10-18
- **Target enrollment:** 130 (ESTIMATED)
- **Last updated:** 2022-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05576324

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05576324, "Effect of the CFTR-modulating Triple Therapy Elexacaftor - Tezacaftor - Ivacaftor". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05576324. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*